Peptidylarginine deiminase 4 (PADI4), a new histone modification enzyme, which converts both arginine and monomethyl-arginine to citrulline, has gained massive attention in recent years as a potential regulator of gene transcription. Recent studies have shown that arginine residues R2, R8, R17, and R26 in the H3 tail and R3 in the H4 tail can be deiminated by PADI4. This kind of histone post-translational modification has the potential to antagonize histone methylation and coordinate with histone deacetylation to regulate gene transcription. PADI4 also deiminates non-histone proteins, such as p300, NPM1, ING4, RPS2, and DNMT3A. PADI4 has been shown to involve in cell apoptosis and differentiation. Moreover, PADI4 can interact with tumor suppressor p53 and regulate the transcriptional activity of p53. Dysregulation of PADI4 is implicated in a variety of diseases, including rheumatoid arthritis, tumor development, and multiple sclerosis. A wide variety of PADI4 inhibitors have been identified. Further understanding of PADI4 functions may lead to novel diagnostic and therapeutic approaches in these diseases. This review summarizes the recent progress in the study of the regulation mechanism of PADI4 on gene transcription and the major physiological functions of PADI4 in human diseases.
Introduction
Peptidylarginine deiminases (PADIs) can catalyze the hydrolysis of peptidylarginine to form peptidyl-citrulline depending on Ca 2+ . Citrullination modification catalyzed by PADIs is also termed deimination for the removal of an amine group in this process [1, 2] . Five members of PADIs have been identified in humans, including PADI1-4 and PADI6. These PADIs are relatively conserved in the Cterminal two-thirds of the sequence and diverge more distantly in the N-terminal one-third of the sequence. The expression patterns of these five types of PADIs are tissue specific [3] . PADI4, which was initially cloned from human myeloid leukemia HL-60 cells induced by retinoic acid [4] , has gained massive attention in recent years as a potential regulator of gene transcription. PADI4 was responsive to estrogen at the transcriptional level through both the classical and nonclassical ER-mediated pathways in MCF-7 cells [5] and was upregulated by tumor necrosis factor-α (TNF-α) in activated macrophages [6] .
In this review, we summarize the recent studies on the PADI4, with a focus on the regulation of deiminase activity, the transcriptional regulation mechanism mediated by PADI4, and the function in cell differentiation and apoptosis, as well as its role in human diseases.
Regulation of PADI4 Enzymatic Activity
Crystal structure of Ca 2+ -free PADI4 shows that the polypeptide chain adopts an elongated fold in which the N-terminal domain forms two immunoglobulin-like subdomains and the C-terminal domain forms an α/β propeller structure [3, 7] . Cys645, the active site nucleophile, exists as the thiolate in the active form of PADI4 and PADI4 utilizes a reverse protonation mechanism [8] . Dimerization of PADI4 can regulate its activity. The ionic interaction between Arg8 and Asp547 and the Tyr435-mediated hydrophobic interaction are determinants of PADI4 dimer. Disrupting the dimer interface of PADI4 decreases its enzymatic activity and calcium binding cooperativity [9] . Besides, protein kinase C (PKC) isoforms play different roles in the regulation of PADI4 activity. PKC-α plays a dominant role in the repression of histone deimination, while PKCζ has the function in the activation of PADI4 [10] .
Histone Deimination Mediated by PADI4 Regulates Gene Transcription Alone or in Combination with Other Histone Modifications
When neutrophils were incubated with calcium ionophore A23187, deimination of histones H2A, H3, and H4 occurred in the nucleus [2] . PADI4 can deiminate arginine residues R2, R8, R17, and R26 in the H3 tail, arginine residue R3 in the H4 tail [11, 12] , as well as histone H2A (Fig. 1) [13] . Histone post-translational modifications (PTMs), including acetylation, methylation, phosphorylation, and deimination, play important roles in the regulation of chromatin structure and gene expression. Corresponding 'de-modifying' enzymes exist to remove the PTM tag returning the protein to its basal state. PADI4 is the first enzyme identified to antagonize histone methylation. It converts unmodified arginine and monomethylated (but not di-methylated) arginine to citrulline at the specific sites on the tails of H3 and H4, providing a way to remove the methyl group from arginine [14] [15] [16] . Deimination mediated by PADI4 may prevent arginine methylation. The sites of arginine residues H3R17 and H4R3 which can be deiminated by PADI4 are also the substrates methylated by arginine methyltransferase CARM1 (H3R17) and PRMT1 (H4R3) (Fig. 1) . PADI4 represses the transcription of estrogen-responsive genes through antagonizing histone methylation modification [14, 15] .
Besides arginine methylation, histone citrullination mediated by PADI4 can also coordinate with histone deacetylation to repress transcription. PADI4 collaborates with histone deacetylase 1 (HDAC1) to generate a repressive chromatin environment on the pS2 promoter [17] . Moreover, PADI4 and HDAC2 can interact with p53 through distinct domains and simultaneously associate with the p21 promoter to regulate gene expression. PADI4 inhibitor (Cl-amidine) and HDAC inhibitor (suberoylanilide hydroxamic acid) show additive effects in inducing p21, GADD45, and PUMA expression and inhibiting the growth of cancer cells in a p53-dependent manner [18] . These studies suggested an important crosstalk and dynamic connection between deimination and deacetylation of histones.
The dynamic structure of chromatin alters the accessibility of the genomic DNA to regulatory factors for a variety of nuclear processes, including transcription and DNA repair. Histone modifications are important mechanisms to regulate chromatin dynamics [19] . Citrullination mediated by PADI4 also affects chromatin structure. PADI4 is able to promote chromatin decondensation and DNA fragmentation [20, 21] . Activation of PADI4 reduces heterochromatin and multilobular nuclear structures in HL- 60 Figure 1 . Schematic representation of the major substrates and regulation mechanism of PADI4 PADI4 deiminates both histone proteins (shown in yellow) and non-histone proteins (shown in green). PADI4 regulates gene transcription alone or in combination with other histone modifications. me, methylation; ac, acetylation.
citrullination of biochemically defined avian nucleosome arrays inhibits the formation of higher order chromatin structures [22] . In addition, citrullination mediated by PADI4 stabilizes the histone H2A/H2B dimmer [23] . Although many reports have indicated that the activity of PADI4 generates a repressive chromatin environment on the target gene promoter [14, 15, 17, 18] , PADI4 can also act as an epigenetic coactivator through counteracting repressive H3R2me2a mark triggered by PRMT6 at the transcription factor Tal1/PADI4 target gene IL6ST, which augments the active H3K4me3 mark and thus increases IL6ST expression during lineage differentiation of hematopoietic stem/progenitor cells [24] . Moreover, PADI4 is enriched in the gene promoter regions near transcription start sites in MCF-7 breast cancer cells and this pattern of binding is primarily associated with actively transcribed genes. Further research showed that following epidermal growth factor stimulation, PADI4 catalytic activity facilitated the phosphorylation of Elk-1, a member of the erythroblast transformation-specific (ETS) oncogene family, histone H4 acetylation, and c-Fos transcriptional activation [25] . These results define a novel function of PADI4 as a transcriptional factor coactivator.
Deimination of Non-histone Proteins Mediated by PADI4
Besides histone substrates, PADI4 can also deiminate many nonhistone proteins. The active PADI4 can remove the methylation of Arg2142 of p300 GRIP1-binding domain, thereby enhancing the p300-GRIP1 (glucocorticoid receptor interacting protein) interaction. These methylation and demethylation events also alter the conformation and activity of the coactivator complex and regulate estrogen receptor-mediated transcription [26] . PADI4 citrullinates the histone chaperone protein, nucleophosmin (NPM1), at the Arg197 in vivo under physiologic conditions, resulting in translocation of NPM1 from the nucleoli to the nucleoplasm [27] . Inhibitor of growth 4 (ING4), a tumor suppressor protein, has also been identified as a novel non-histone substrate of PADI4. PADI4 preferentially citrullinates NLS region of ING4, which is essential for the binding between ING4 and p53, thereby resulting in the repression of p53 transactivity and increased susceptibility of ING4 to degradation [28] . Moreover, PADI4 can citrullinate the Arg-Gly repeat region of human 40S ribosomal protein S2 (RPS2), which is also an established site for Arg methylation by protein arginine methyltransferase 3. Citrullination participates in the regulation of RPS2 and ribosome assembly [29] . It has been reported that PADI4 can interact with de novo DNA methyltransferase DNMT3A and citrullinate the sequence upstream of its PWWP domain. Citrullination by PADI4 increases the protein stabilization and DNA methyltransferase activity of DNMT3A, which provides a novel mechanism for controlling de novo DNA methylation [30] (Fig. 1) .
Role of PADI4 in Cell Differentiation and Apoptosis
The protein and mRNA levels of PADI4 are increased during granulocyte and monocyte differentiation in human myeloid leukemia HL-60 cells [4] , and the PADI4/SOX4/PU.1 signaling pathway is involved in the committed differentiation [31] . PADI4 inhibitor Clamidine treatment or siRNA knockdown of PADI4 can induce differentiation of HT29 colon cancer cells [32] . In our onging research, we discovered that PADI4 also participates in osteoblast differentiation (to be published).
PADI4 also plays important roles in cell apoptosis. Protein deimination occurs during the process of apoptosis and overexpression of PADI4 induces apoptosis, which is mainly through cell cycle arrest in G1 phase and a mitochondria-mediated pathway [33] . In another report, Padi4 −/− mice exhibited resistance to radiationinduced apoptosis in the thymus [20] . However, there are still different opinions on how Cl-amidine treatment or PADI4 knockdown induces apoptosis in U2OS osteosarcoma cells [34, 35] . The role of PADI4 in cell apoptosis may be cell type-specific [36] .
PADI4 is Involved in the Occurrence and Development of Some Human Diseases

PADI4 and tumor development
Recent studies showed that PADI4 had significant expression in various malignant tissues but maintained a low level of expression in normal and benign tissues [37] . PADI4 may be involved in tumourigenesis via the citrullination of histone, cytokeratin, antithrombin, and fibronectin [38, 39] . PADI4 may also contribute to the disrupted apoptosis of tumors by caspase-mediated cleavage of cytokeratin [34] . Overexpression of PADI4 constrains the activity of epithelial-mesenchymal transition, which has been reported to induce resistance in tumor cells, via suppressing ETS-domain-containing protein expression, and inhibits resistance of non-small cell lung cancer to gefitinib [40] . PADI4 contributes to gastric tumorigenesis by upregulating the expressions of CXCR2, KRT14, and TNF-α, which activates angiogenesis, cell proliferation, cell migration, and the immune microenvironment in tumors [41] . A number of studies have focused on the relationship between PADI4 and tumor suppressor p53, a sequence-specific transcription factor. p53 is activated upon many cellular stresses and responds to these stress events via regulating cell cycle progression, apoptosis, DNA repair, senescence, cellular metabolism, or autophagy [42, 43] . PADI4 can bind to the C-terminus of p53 and is involved in the repression of p53 transcriptional activity, which suggests that PADI4 is a co-repressor of p53. Histone arginine methylation plays important roles in transcriptional activation of p53 target genes. PADI4 can be recruited by p53 to the promoter of these genes and reverses this modification, thereby repressing the expressions of p53 target genes including p21/CIP1/WAF1 and OKL38 [44] . As previously mentioned, citrullination of ING4 mediated by PADI4 loses its affinity for p53 and the promotion of p53 acetylation, resulting in repression of downstream p21 expression [28] . PADI4 can be transactivated by p53 through an intronic p53-binding site, and in the same way p53 also regulates protein citrullination. H4R3 was citrullinated in DNA damage response in a p53/PADI4-dependent manner and the level of cit-H4R3 was negatively correlated with p53 protein expression and with tumor size in non-small cell lung cancer tissues. Lamin C was citrullinated at its C-terminus in DNA damage response also in a p53/ PADI4-dependent manner [20] . Our ongoing research suggested that PADI4 can deiminate p53 directly and repress p53 acetylation (to be published). These findings indicate that PADI4 plays important role in tumor development probably through the interaction with p53 and the regulation of p53 transcriptional activity.
PADI4 and rheumatoid arthritis
The most definite function of PADI4 in human diseases is the close relationship between PADI4 gene polymorphisms and rheumatoid arthritis (RA) risk [45] [46] [47] [48] [49] . In addition, high levels of PADI4 protein are expressed in the inflamed synovium of RA patients [50] [51] [52] [53] [54] [55] [56] . The role of PADI4 in early RA pathogenesis is mainly through promoting the generation of citrullinated autoantigens [57, 58] . PADI4 has been identified as a new therapeutic target for RA treatment [59] [60] [61] [62] . PADI4 is also overexpressed in the multiple sclerosis [63, 64] , and heterozygote genotypes for PADI4_89 were protectively associated with susceptibility to tuberculosis in Koreans [65] ; however, the underlying mechanism remains unclear.
Because of the important role of PADI4 in human diseases, the development of PADI4 inhibitor is of paramount importance [66, 67] . Several inhibitors of PADI4 have been identified [66, 68, 69] , for example, F-and Cl-amidine [70, 71] , Thr-Asp-F-amidine [67] , GSK199 [72] , and so on [73, 74] . Cl-amidine can also suppress colitis by driving apoptosis of inflammatory cells and is a candidate therapeutic drug for inflammatory bowel diseases [75, 76] . YW3-56 is identified as a novel PADI4 inhibitor, and SESN2 is one of the YW3-56 target genes which encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 signaling pathway [77] .
Conclusions and Perspectives
PADI4 can convert both Arg and monomethyl-Arg to citrulline and this PTM plays important roles in gene transcriptional regulation alone or in combination with other histone modifications. PADI4 also deiminates many non-histone proteins and is involved in a variety of cell signaling pathways, including apoptosis and differentiation. PADI4 is closely related to many diseases, including cancer, rheumatoid arthritis, and multiple sclerosis. Further studies of the underlying mechanism for PADI4 involved in these diseases may provide new insights for the diagnosis and treatment of these diseases.
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